para metallation of 3-acetyl-chromen-2-one Schiff bases in tetranuclear palladacycles: focus on their biomolecular interaction and in vitro cytotoxicity

Dalton Transactions : an International Journal of Inorganic Chemistry
G KalaiarasiR Prabhakaran

Abstract

Three tetranuclear (1-3) complexes and a mononuclear (4) palladium(ii) complex were synthesized from 3-acetyl-chromen-2-one Schiff base ligands [H2-3MAC-Rtsc] (where R = H [H2-3MAC-tsc]; CH3[H2-3MAC-mtsc]; C2H5[H2-3MAC-etsc] or C6H5[H2-3MAC-ptsc]) and potassium tetrachloropalladate. Their formation was confirmed by spectroscopic techniques and X-ray crystallographic analysis. Their ability to bind with DNA and albumin was analysed by using absorption and emission titrations. The MTT assay was carried out to analyze the anticancer potential of the ligands and synthesized complexes against HepG2 (human liver cancer) and HT-29 (human colon cancer) cells. In addition, the compounds were less toxic when tested against the human normal keratinocyte cells (HaCaT). Ligands and complexes displayed better cytotoxicity with lower IC50 values than the standard drug cisplatin. Further AO-EB and DAPI staining assays were carried out to detect the mode of cell death induced by the complexes i.e. apoptosis or necrosis. The complex 3 showed better cytotoxicity and was further subjected to flow cytometric analysis. The results suggested that the complex 3 induced apoptotic cell death.

References

Mar 1, 1989·Electroencephalography and Clinical Neurophysiology·L P PanychM P Beddoes
Jun 9, 2005·Chemical Reviews·Jairton DupontJohn Spencer
Aug 16, 2005·Inorganic Chemistry·Abdellatif ChouaiRandolph P Thummel
May 23, 2006·Current Medicinal Chemistry·Adnan Salim Abu-Surrah, Mika Kettunen
Feb 19, 2008·Cancer Treatment Reviews·Andreas A ArgyriouHaralabos P Kalofonos
Jan 14, 2009·Molecular Cancer Therapeutics·Sarah R McWhinneyHoward L McLeod
Mar 12, 2009·Anti-cancer Agents in Medicinal Chemistry·Enjun GaoLei Liu
May 18, 2010·Organic & Biomolecular Chemistry·Madavu Salian SubhasSuresh K Bhargava
Jun 16, 2010·Anti-cancer Agents in Medicinal Chemistry·Xiaoyong Wang
Jun 15, 2011·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Sangamesh A PatilPrema S Badami
Nov 22, 2011·Metallomics : Integrated Biometal Science·Eswaran RamachandranKaruppannan Natarajan
Sep 29, 2012·Dalton Transactions : an International Journal of Inorganic Chemistry·Alfonso CastiñeirasLourdes Gómez-Rodríguez
Dec 12, 2012·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·P KavithaK Laxma Reddy
Dec 30, 2014·Acta Crystallographica. Section A, Foundations and Advances·George M Sheldrick
Jan 7, 2015·Dalton Transactions : an International Journal of Inorganic Chemistry·Muneebah AdamsGregory S Smith
Aug 2, 2015·European Journal of Medicinal Chemistry·Dnyanesh S RanadePrasad P Kulkarni
Aug 25, 2015·European Journal of Medicinal Chemistry·Kishna Ram SenwarNagula Shankaraiah
Sep 19, 2016·European Journal of Medicinal Chemistry·Tatjana Gazivoda KraljevićSilvana Raić-Malić
Dec 21, 2016·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Jebiti HaribabuRamasamy Karvembu

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
fluorescence spectroscopy
light microscopy

Software Mentioned

SHELXL
Crystal Clear
PLATON98
PLATON
CrysAlicPro
SQUEEZE
ORTEP
SHELXT
WinGX

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis